Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Accumulated Expenses (2016 - 2026)

Ocular Therapeutix has reported Other Accumulated Expenses over the past 14 years, most recently at $1.7 million for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses rose 4.19% year-over-year to $1.7 million; the TTM value through Mar 2026 reached $1.7 million, up 4.19%, while the annual FY2025 figure was $1.9 million, 6.76% down from the prior year.
  • Other Accumulated Expenses for Q1 2026 was $1.7 million at Ocular Therapeutix, down from $1.9 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $2.1 million in Q4 2024 and troughed at $1.1 million in Q2 2022.
  • A 5-year average of $1.6 million and a median of $1.6 million in 2024 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 61.58% in 2024 and later decreased 10.53% in 2025.
  • Year by year, Other Accumulated Expenses stood at $1.2 million in 2022, then rose by 24.19% to $1.5 million in 2023, then surged by 34.75% to $2.1 million in 2024, then dropped by 6.76% to $1.9 million in 2025, then dropped by 13.0% to $1.7 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for OCUL at $1.7 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.